![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NAMPT |
Gene summary for NAMPT |
![]() |
Gene information | Species | Human | Gene symbol | NAMPT | Gene ID | 10135 |
Gene name | nicotinamide phosphoribosyltransferase | |
Gene Alias | 1110035O14Rik | |
Cytomap | 7q22.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024R718 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10135 | NAMPT | ATC5 | Human | Thyroid | ATC | 3.85e-18 | 1.23e-01 | 0.34 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00362939 | Breast | Precancer | response to decreased oxygen levels | 53/1080 | 322/18723 | 4.09e-12 | 6.84e-10 | 53 |
GO:00704829 | Breast | Precancer | response to oxygen levels | 55/1080 | 347/18723 | 7.47e-12 | 1.11e-09 | 55 |
GO:00362948 | Breast | Precancer | cellular response to decreased oxygen levels | 31/1080 | 161/18723 | 2.61e-09 | 2.11e-07 | 31 |
GO:00714538 | Breast | Precancer | cellular response to oxygen levels | 32/1080 | 177/18723 | 7.32e-09 | 5.52e-07 | 32 |
GO:00709979 | Breast | Precancer | neuron death | 50/1080 | 361/18723 | 7.75e-09 | 5.70e-07 | 50 |
GO:00091179 | Breast | Precancer | nucleotide metabolic process | 56/1080 | 489/18723 | 7.40e-07 | 3.00e-05 | 56 |
GO:00067539 | Breast | Precancer | nucleoside phosphate metabolic process | 56/1080 | 497/18723 | 1.24e-06 | 4.70e-05 | 56 |
GO:00075653 | Breast | Precancer | female pregnancy | 29/1080 | 193/18723 | 2.07e-06 | 7.31e-05 | 29 |
GO:00447063 | Breast | Precancer | multi-multicellular organism process | 31/1080 | 220/18723 | 3.73e-06 | 1.19e-04 | 31 |
GO:00075688 | Breast | Precancer | aging | 41/1080 | 339/18723 | 5.95e-06 | 1.71e-04 | 41 |
GO:00313309 | Breast | Precancer | negative regulation of cellular catabolic process | 34/1080 | 262/18723 | 8.16e-06 | 2.20e-04 | 34 |
GO:00091655 | Breast | Precancer | nucleotide biosynthetic process | 32/1080 | 254/18723 | 2.72e-05 | 6.21e-04 | 32 |
GO:19012935 | Breast | Precancer | nucleoside phosphate biosynthetic process | 32/1080 | 256/18723 | 3.18e-05 | 6.97e-04 | 32 |
GO:00342849 | Breast | Precancer | response to monosaccharide | 29/1080 | 225/18723 | 4.19e-05 | 9.00e-04 | 29 |
GO:00097439 | Breast | Precancer | response to carbohydrate | 31/1080 | 253/18723 | 6.15e-05 | 1.25e-03 | 31 |
GO:00093148 | Breast | Precancer | response to radiation | 47/1080 | 456/18723 | 8.39e-05 | 1.62e-03 | 47 |
GO:00712147 | Breast | Precancer | cellular response to abiotic stimulus | 37/1080 | 331/18723 | 9.12e-05 | 1.73e-03 | 37 |
GO:01040047 | Breast | Precancer | cellular response to environmental stimulus | 37/1080 | 331/18723 | 9.12e-05 | 1.73e-03 | 37 |
GO:00098959 | Breast | Precancer | negative regulation of catabolic process | 36/1080 | 320/18723 | 9.92e-05 | 1.83e-03 | 36 |
GO:00102125 | Breast | Precancer | response to ionizing radiation | 21/1080 | 148/18723 | 1.19e-04 | 2.13e-03 | 21 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa046219 | Esophagus | HGIN | NOD-like receptor signaling pathway | 45/1383 | 186/8465 | 3.40e-03 | 2.54e-02 | 2.02e-02 | 45 |
hsa0462114 | Esophagus | HGIN | NOD-like receptor signaling pathway | 45/1383 | 186/8465 | 3.40e-03 | 2.54e-02 | 2.02e-02 | 45 |
hsa0462122 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
hsa0462132 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
hsa046212 | Lung | IAC | NOD-like receptor signaling pathway | 38/1053 | 186/8465 | 1.23e-03 | 8.24e-03 | 5.47e-03 | 38 |
hsa0462111 | Lung | IAC | NOD-like receptor signaling pathway | 38/1053 | 186/8465 | 1.23e-03 | 8.24e-03 | 5.47e-03 | 38 |
hsa046218 | Oral cavity | OSCC | NOD-like receptor signaling pathway | 108/3704 | 186/8465 | 5.13e-05 | 2.07e-04 | 1.05e-04 | 108 |
hsa0462113 | Oral cavity | OSCC | NOD-like receptor signaling pathway | 108/3704 | 186/8465 | 5.13e-05 | 2.07e-04 | 1.05e-04 | 108 |
hsa0462121 | Oral cavity | LP | NOD-like receptor signaling pathway | 73/2418 | 186/8465 | 9.80e-04 | 4.53e-03 | 2.92e-03 | 73 |
hsa0462131 | Oral cavity | LP | NOD-like receptor signaling pathway | 73/2418 | 186/8465 | 9.80e-04 | 4.53e-03 | 2.92e-03 | 73 |
hsa046214 | Oral cavity | EOLP | NOD-like receptor signaling pathway | 48/1218 | 186/8465 | 2.51e-05 | 1.31e-04 | 7.70e-05 | 48 |
hsa046215 | Oral cavity | EOLP | NOD-like receptor signaling pathway | 48/1218 | 186/8465 | 2.51e-05 | 1.31e-04 | 7.70e-05 | 48 |
hsa046216 | Oral cavity | NEOLP | NOD-like receptor signaling pathway | 39/1112 | 186/8465 | 1.79e-03 | 7.91e-03 | 4.98e-03 | 39 |
hsa046217 | Oral cavity | NEOLP | NOD-like receptor signaling pathway | 39/1112 | 186/8465 | 1.79e-03 | 7.91e-03 | 4.98e-03 | 39 |
hsa04621 | Stomach | WIM | NOD-like receptor signaling pathway | 15/284 | 186/8465 | 1.44e-03 | 1.30e-02 | 1.04e-02 | 15 |
hsa046211 | Stomach | WIM | NOD-like receptor signaling pathway | 15/284 | 186/8465 | 1.44e-03 | 1.30e-02 | 1.04e-02 | 15 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
NAMPT | INSR | NAMPT_INSR | VISFATIN | Breast | ADJ |
NAMPT | ITGA5_ITGB1 | NAMPT_ITGA5_ITGB1 | VISFATIN | Breast | ADJ |
NAMPT | ITGA5_ITGB1 | NAMPT_ITGA5_ITGB1 | VISFATIN | Breast | DCIS |
NAMPT | INSR | NAMPT_INSR | VISFATIN | Breast | Healthy |
NAMPT | ITGA5_ITGB1 | NAMPT_ITGA5_ITGB1 | VISFATIN | Breast | Healthy |
NAMPT | INSR | NAMPT_INSR | VISFATIN | Breast | IDC |
NAMPT | ITGA5_ITGB1 | NAMPT_ITGA5_ITGB1 | VISFATIN | Breast | IDC |
NAMPT | INSR | NAMPT_INSR | VISFATIN | Breast | Precancer |
NAMPT | ITGA5_ITGB1 | NAMPT_ITGA5_ITGB1 | VISFATIN | Breast | Precancer |
NAMPT | INSR | NAMPT_INSR | VISFATIN | Cervix | ADJ |
NAMPT | ITGA5_ITGB1 | NAMPT_ITGA5_ITGB1 | VISFATIN | Cervix | ADJ |
NAMPT | INSR | NAMPT_INSR | VISFATIN | Cervix | Healthy |
NAMPT | INSR | NAMPT_INSR | VISFATIN | Cervix | Precancer |
NAMPT | ITGA5_ITGB1 | NAMPT_ITGA5_ITGB1 | VISFATIN | Cervix | Precancer |
NAMPT | INSR | NAMPT_INSR | VISFATIN | CRC | ADJ |
NAMPT | ITGA5_ITGB1 | NAMPT_ITGA5_ITGB1 | VISFATIN | CRC | ADJ |
NAMPT | INSR | NAMPT_INSR | VISFATIN | CRC | CRC |
NAMPT | ITGA5_ITGB1 | NAMPT_ITGA5_ITGB1 | VISFATIN | CRC | CRC |
NAMPT | INSR | NAMPT_INSR | VISFATIN | CRC | FAP |
NAMPT | INSR | NAMPT_INSR | VISFATIN | CRC | Healthy |
Page: 1 2 3 4 5 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NAMPT | SNV | Missense_Mutation | novel | c.397N>C | p.Thr133Pro | p.T133P | P43490 | protein_coding | deleterious(0) | possibly_damaging(0.497) | TCGA-A2-A3XY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD |
NAMPT | SNV | Missense_Mutation | c.318N>C | p.Glu106Asp | p.E106D | P43490 | protein_coding | tolerated(0.48) | benign(0) | TCGA-BH-A0BL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
NAMPT | SNV | Missense_Mutation | c.1237N>C | p.Val413Leu | p.V413L | P43490 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-D8-A1JC-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
NAMPT | SNV | Missense_Mutation | novel | c.722N>T | p.Ser241Phe | p.S241F | P43490 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
NAMPT | SNV | Missense_Mutation | novel | c.182N>T | p.Gly61Val | p.G61V | P43490 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-PL-A8LZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
NAMPT | SNV | Missense_Mutation | c.857N>T | p.Ala286Val | p.A286V | P43490 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
NAMPT | SNV | Missense_Mutation | novel | c.1211T>C | p.Val404Ala | p.V404A | P43490 | protein_coding | tolerated(0.74) | benign(0.096) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
NAMPT | SNV | Missense_Mutation | c.686A>C | p.Lys229Thr | p.K229T | P43490 | protein_coding | tolerated(0.09) | possibly_damaging(0.49) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
NAMPT | SNV | Missense_Mutation | c.571N>A | p.His191Asn | p.H191N | P43490 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-A5-A0GU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NAMPT | SNV | Missense_Mutation | novel | c.238N>G | p.Ile80Val | p.I80V | P43490 | protein_coding | tolerated(0.21) | probably_damaging(0.94) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10135 | NAMPT | DRUGGABLE GENOME | GMX1777 | TEGLARINAD CHLORIDE | ||
10135 | NAMPT | DRUGGABLE GENOME | GMX1777 | TEGLARINAD CHLORIDE | ||
10135 | NAMPT | DRUGGABLE GENOME | CHS-828 | CHS-828 | ||
10135 | NAMPT | DRUGGABLE GENOME | Daporinad | DAPORINAD | ||
10135 | NAMPT | DRUGGABLE GENOME | inhibitor | CHEMBL190412 | TEGLARINAD CHLORIDE |
Page: 1 |